MATERIALS AND METHODS

Animals.
C3H or CD-1 female mice (8 weeks old) were obtained from Charles River (Milano, Italy). All experiments were performed in accordance with the Universities Federation for Animal Welfare Handbook on the Care and Management of Laboratory Animals and the guidelines of the animal ethics committee of the University of Cagliari.
Induction of Liver Cell Proliferation.
In experimental protocol 1 (Fig. 1A) , hepatocyte proliferation was induced by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) (3 mg/kg body weight, dissolved in dimethyl sulphoxidecorn oil solution; Sigma-Aldrich, Milan, Italy). Controls received an equivalent amount of the vehicle. To determine the proliferative response of the liver to TCPOBOP, mice were given 2-bromodeoxyuridine (BrdU) dissolved in drinking water (1 mg/mL; Sigma-Aldrich, Milan, Italy) and sacrificed 1 week later. In experimental protocol 2 ( Fig. 2A ), mice were treated as in protocol 1 except that they were sacrificed 24 hours, 36 hours, and 1 week after one dose or 24 and 36 hours after two doses of TCPOBOP. BrdU dissolved in drinking water was given as shown in Fig. 2A .
Generation of Lentiviral Vectors, Lentivirus Production, and Mice Injection.
The p2xFlag CMV-YAP vector (a kind gift from M. Sudol) was digested with EcoRI, blunted, and the entire YAP complementary DNA (cDNA) was moved in the EcoRV site of the lentiviral vector p156RRLsin.PPTh CMV.MCS.pre. Lentiviruses were produced as described. 23 The concentration of viral p24 antigen was assessed using the HIV-1 p24 core profile enzyme-linked immunosorbent assay kit (NEN Life Science Products) according to the manufacturer's instructions. For in vivo studies, viral particles of mutated YAP (mYAP) (Ser 127 Ala and Ser 381 Ala) and control vector were purified by way of ultracentrifugation and suspended in sterile, endotoxin-free phosphatebuffered saline. Viral particles (20 μg of purified p24/mice in 400 μL phosphate-buffered saline) were injected into the tail vein of CD-1 mice 3 days after the first and 4 days prior to the second TCPOBOP administration (Fig. 3A) .
Chemically Induced Liver Carcinogenesis Protocol.
A single intraperitoneal dose of diethylnitrosamine (DENA) (90 mg/kg body weight; Sigma) was injected, followed 1 week later by TCPOBOP administration (3 mg/kg) once a week for 27 weeks.
Two control groups, one receiving DENA alone, the other treated with TCPOBOP alone for 27 weeks, were also included. All mice received BrdU in drinking water for 3 days before being sacrificed (Fig. 4A) .
Immunohistochemistry BrdU Staining.
BrdU was stained with a mouse antibody from Becton Dickinson (San Jose, CA) as described. 24 Labeling index was expressed as the number of BrdU-positive hepatocyte nuclei per 100 nuclei. Results are expressed as the mean ± SD. At least 2,500 hepatocyte nuclei for each liver were scored.
YAP Staining.
Tissue sections were subjected to Target Retrieval Solution (Dako, Glostrup, Denmark) and exposed to four cycles at 700 W in a microwave oven. After washing with Dako Wash Buffer, endogenous peroxidase was blocked with Dako Blocking Buffer for 5 minutes at room temperature.
The sections were incubated with the polyclonal antibody anti-YAP (Santa Cruz Biotechnology, Inc. Santa Cruz, CA) for 60 minutes at a dilution of 1:100. The final reaction was visualized using 3,3'-diaminobenzidine.
Quantitative Reverse-Transcription Polymerase Chain Reaction
Analysis of MicroRNA-375.
Total RNA was extracted from frozen liver samples using Trizol Reagent (Invitrogen). cDNA was Glyceraldehyde 3-phosphate dehydrogenase was used as an endogenous normalizer.
Western Blot Analysis
Total cell and nuclear extracts were prepared from frozen livers as described. 24 
Statistical Analysis
Comparison between the treated and control group was performed with a nonparametric MannWhitney test.
RESULTS
Enlarged Livers Become Rapidly Refractory to Further Growth Stimuli.
As schematically represented in Fig.1A , mice were injected with a single dose of TCPOBOP or oil and sacrificed 1 week later. As shown in Fig. 1B , a single dose of TCPOBOP elicited a massive enlargement of the liver that doubled 7 days after mitogen administration (liver weight/body weight 10.96% versus 5.31% in controls). Liver enlargement was due, at least in part, to hepatocyte proliferation, as shown by the striking increase in BrdU incorporation (labeling index 43.95% versus 3.83% in controls) (Fig. 1C) . Administration of a second dose of TCPOBOP 1 week after the first treatment (Fig. 1A, bottom) , a time when the liver was twice the size of the normal adult liver, did not cause any further enlargement of the organ (liver weight/body weight 11.39% versus 10.96%) (Fig. 1B) . Accordingly, no increase in BrdU incorporation was observed in this group (5.91% versus 43.95% of mice treated with only one dose; 3.83% in controls) (Fig. 1C) . Because most of the effects of TCPOBOP are mediated by binding and activation of constitutive androstane receptor (CAR), we considered the possibility that the lack of proliferative response of the enlarged liver could be due to down-regulation or functional inactivation of CAR. We thus evaluated the expression of Cyp2b10, a specific CAR target gene (Fig. 1D) , and found that Cyp2b10 expression was increased almost 30-fold over control values both after the first as well as the second dose of TCPOBOP, thus showing that CAR was active in both the conditions. These results suggest that the refractoriness of the enlarged liver to a second mitogenic stimulus is not due to lack of CAR transcriptional activity, but likely to the ability of the liver to sense its oversize and to trigger pathways aimed at inhibiting further growth.
YAP Levels Are Increased in Mouse Hepatocytes Treated with 1 Dose of TCPOBOP.
To determine whether dysregulation of the Hippo pathway was involved in the initial mitogenic response elicited by TCPOBOP, we treated the animals with either oil or TCPOBOP and sacrificed them 24 and 36 hours or 1 week after one dose, and 24 and 36 hours after two doses of TCPOBOP ( Fig. 2A) . As shown in Fig. 2B and 2C, BrdU incorporation was significantly increased 24 and 36 hours after a single dose of TCPOBOP, and returned to basal values 1 week after treatment. The increased labelling index was associated with increased protein levels of cyclin D1, cyclin A, and PCNA (Fig. 2D) . Notably, YAP levels were also increased at these time points, indicating a dysregulation of the Hippo pathway during TCPOBOP-induced hepatocyte proliferation; the return of YAP levels to control values 1 week after treatment suggests reactivation of the Hippo pathway, leading to block of hepatocyte proliferation. Notably, when a second dose of TCPOBOP was administered 1 week after the first dose, namely at a time when the size of the liver was twice that of controls ( Fig. 2A, lower part) , only a very slight increase of BrdU incorporation (Fig. 2B,C ) and YAP expression (Fig. 2D ) was observed between 24 or 36 hours after mitogen administration. Accordingly, coactivating activity of YAP evaluated by measuring the expression levels of Birc-5/survivin, a target gene of YAP,17 revealed a 20-fold increase in the expression of this gene in the livers of mice sacrificed 24 hours after the first dose, but only a twofold increase after the second dose of TCPOBOP (Fig. 2E) . These findings suggest that YAP transitions from an active to an inactive state and is involved in the refractoriness of enlarged livers to a second mitogenic challenge. In this context, it is noteworthy that almost no residual hepatocyte proliferation occurs in mice exposed to the second dose of TCPOBOP after the first 36 hours, as also indicated in Fig. 1C . (Fig. 3A,B ) did override the physiological termination of liver growth. Indeed, whereas no proliferation was observed after the second dose of TCPOBOP in mice transduced with control vector, a significant increase of cell proliferation was observed when TCPOBOP was given to mice infected with the active YAP (6.54% of BrdU-positive nuclei versus 16.31%; P < 0.01) (Fig. 3,C,D) . To investigate whether injection of mYAP could per se lead to hepatocyte proliferation regardless of TCPOBOP administration, we injected untreated mice with YAP lentiviruses and compared the proliferative response of hepatocytes with that of mice receiving two administrations of TCPOBOP, in the presence or absence of exogenous YAP (Fig. 3E) . A further experimental group was treated with control lentiviruses. As shown in Fig. 3F , transduction of hepatocytes with YAP alone induced only a slight and not statistically significant increase of BrdU incorporation over control values. On the other hand, liver transduction with YAP of mice treated with TCPOBOP led to a highly significant increase in proliferation compared with TCPOBOP-treated mice transduced with control virus. These experiments strongly suggest that the Hippo pathway is involved in the refractoriness of enlarged liver to further mitogenic stimuli.
The Hippo Pathway Is Dysregulated in HCC.
Overexpression of YAP has been observed in many human tumors, enough that it is considered a candidate oncogene.22, 27 Despite the fact that TCPOBOP-induced enlarged livers do not grow further once they reach a certain size, they nevertheless develop HCC upon an initiating dose of a chemical carcinogen followed by repeated treatments with the mitogen.8, 28 We thus hypothesized that carcinogen-induced mutations could favor the escape of resistant cells from the growthsuppressive environment regulating normal hepatocytes, thus allowing them to proliferate and progress to HCC. To determine the status of the Hippo pathway in HCC, we adopted an experimental protocol wherein mice were given an initiating dose of DENA, followed by repeated injections of TCPOBOP for 27 weeks (Fig. 4A) . Control mice were given DENA or TCPOBOP alone. As shown, the livers of mice treated with 27 injections of TCPOBOP were only twice that of controls, confirming the existence of a strict regulation of liver size (Fig 4B,C) . Whereas at the time of sacrifice, control mice and animals treated with TCPOBOP alone were completely devoid of tumors, livers from all mice exposed to DENA+TCPOBOP exhibited multiple tumors (Fig. 4C) , which on histological examination showed nuclear atypia, cellular pleomorphism, and increased trabecular size and were therefore classified as medium-to high-grade HCCs (Fig. 4D) . All tumors showed a high proliferative rate as detected by way of BrdU immunohistochemistry (Fig. 4E); conversely, only a negligible proliferative activity was observed in nontumoral areas of the liver or in the liver from mice treated with TCPOBOP or DENA alone (Fig. 4E) .
Western blot analysis on total cellular lysates (Fig. 5A ) of 21 HCCs, revealed in most of the tumors a significant increase in the levels of YAP compared with those of mice treated with TCPOBOP alone or DENA alone. Notably, a remarkable increase of YAP levels was observed in the nuclear fraction of randomly selected HCCs (5B, top). Accordingly, immunohistochemical staining revealed the presence of several YAP-positive cells in the tumors (Fig. 5C ), whereas no positive hepatocytes were observed in the livers of mice treated with DENA or TCPOBOP (data not shown). Notably, YAP was localized mainly in the nucleus of tumoral hepatocytes, although a cytoplasmic localization was also observed. No major changes of phosphorylated YAP were detected in the cytosolic fractions between tumors and normal or hyperplastic livers (Fig. 5B,   bottom ).
To prove that YAP was indeed more active in HCCs, we evaluated the level of expression of two other genes that are direct transcriptional targets of YAP, namely AFP and CTGF.15, 17 As shown in Fig. 6A ,B, we found that the expression of these two genes was up-regulated in HCCs, 100% of the tumors showing increased expression of AFP and 60% exhibiting increased levels of CTGF.
miR-375 Is Down-regulated in HCC.
It was shown recently that miR-375 regulates the expression of YAP and is down-regulated in human HCC.29 To verify whether down-regulation of miR-375 is associated with increased YAP expression in mouse HCC, we performed a real-time PCR analysis of miR-375 expression in 21
HCCs developed in DENA+TCPOBOP-treated mice and in livers from animals treated with DENA or TCPOBOP alone. Fig.6C shows that miR-375 was significantly down-regulated in HCC (17/21) (P < 0.01) and was inversely correlated with the protein levels of YAP (Fig. 5A) . These findings support the notion that YAP is a direct target of miR-375, and suggests a role for miR-375 in the increased expression of YAP in HCCs. The first question we asked was whether in nontransgenic mice, the Hippo pathway is involved in the adaptive liver enlargement that follows treatment with the CAR agonist, TCPOBOP, a wellknown inducer of hepatocyte proliferation. Our study demonstrates that liver enlargement caused by TCPOBOP is associated with a temporary inactivation of the suppressive action of the Hippo pathway; indeed, increased levels of YAP paralleled the enhanced hepatocyte proliferation.
DISCUSSION
Notably, a return to basal levels of YAP occurred 1 week after TCPOBOP treatment, a time when proliferation had ceased; this suggests that the Hippo pathway is reactivated once the organ has reached a mass that is twice that of control liver.
We showed that a second treatment with TCPOBOP did not lead to further increase of the liver, demonstrating that this organ rapidly senses its oversize and activates mechanisms to inhibit additional growth. This was not due to lack of CAR activation by TCPOBOP, because the expression of the CAR target gene Cyp2b10 was significantly increased after the second dose of TCPOBOP, when proliferation was not observed. An important role in establishing the refractoriness of enlarged livers to further mitogenic stimuli might be played by the Hippo pathway. between YAP activation and HCC development, the outcome of this study suggests nevertheless that the Hippo pathway can play an important role in HCC development also in non-genetically manipulated animals; moreover, it further supports the notion that pathways governing tissue overgrowth should be deeply explored as potential therapeutic targets in human HCC.
